Mitochondrial Signal • The Exercise Peptide
MOTS-c is a 16-amino-acid peptide naturally encoded by mitochondrial DNA. It acts like a mitochondrial hormone, signaling cells to improve glucose uptake, burn fuel more efficiently, and adapt to metabolic stress.
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA type-c. It is a naturally occurring, 16-amino-acid peptide encoded within your mitochondrial DNA. Most peptides are encoded by DNA in the cell’s nucleus, which makes MOTS-c part of a rare group of mitochondrial signaling peptides.
Your body already makes MOTS-c, and exercise can increase its levels in muscle and the bloodstream. It acts as a mitochondrial hormone, helping cells respond to changes in energy demand. A key part of that response involves AMPK, often called the cell’s metabolic master switch. In preclinical studies, MOTS-c activates this pathway to support glucose uptake, fat metabolism, and adaptation to metabolic stress.
MOTS-c was first identified in 2015 by researchers at the University of Southern California. Since then, preclinical research has explored its effects on metabolism, aging, exercise performance, bone health, cardiovascular function, and more. Direct human clinical data on MOTS-c itself remains extremely limited. CB4211, a stabilized synthetic analog developed by CohBar, completed a Phase 1a/1b trial in 2021 with company-reported positive safety findings and early metabolic signals. Those results are encouraging, but they do not establish the effectiveness of native MOTS-c.
MOTS-c is not FDA approved for human use. WADA explicitly named it as an example of a prohibited AMPK activator in 2024 under section S4.4, Metabolic Modulators. It remained prohibited in 2025 and 2026, both in and out of competition, in sports governed by the World Anti-Doping Code.
In cell studies, MOTS-c alters the folate–purine pathway, increasing AICAR and activating AMPK, the cell’s energy sensor. This supports glucose uptake, fat oxidation, and metabolic flexibility—switching between carbohydrate and fat for fuel. Animal studies also show increased muscle GLUT4 glucose transporters, helping explain its exercise-mimetic role.
Under metabolic or oxidative stress, MOTS-c can enter the nucleus within about 30 minutes in cultured cells. This AMPK-dependent movement allows it to associate with DNA and NRF2, helping regulate antioxidant defenses and stress-response genes.
A small human cycling study found muscle MOTS-c rose approximately 12-fold after exercise; blood levels increased 50%–60% before returning to baseline after four hours. Animal and cell studies show improved muscle glucose uptake and insulin sensitivity. The human findings describe a natural exercise response, not the effects of injections.
A 2026 mouse study by Gudiksen and colleagues found better muscle mitochondrial performance without increased respiratory protein content—improved function of existing machinery. The effects depended on AMPK and PGC-1α and included lower reactive oxygen species (ROS) release and oxidative protein damage. This points to mitochondrial quality, not simply quantity.
In mouse models of inflammatory injury, MOTS-c reduced IL-6, IL-1β, and TNF-α while increasing anti-inflammatory IL-10. Whether these effects translate into clinical benefits in people remains unproven.
AMPK can oppose mTORC1 growth signaling, making endurance or metabolic conditioning a closer mechanistic fit than dosing immediately before heavy hypertrophy training. This timing rationale comes from pathway biology, not controlled human MOTS-c timing trials.
MOTS-c is most strongly associated with improved glucose tolerance and insulin sensitivity in animal models, including insulin-independent glucose uptake through GLUT4 signaling.
In high-fat diet models, MOTS-c helped prevent diet-induced weight gain and metabolic dysfunction by improving fuel utilization.
Preclinical studies show improved running capacity, grip strength, stride length, and physical function in young and aged animals.
Circulating MOTS-c levels decline with age and correlate with worsening metabolic health and reduced physical capacity.
Animal studies show improved cardiac function, reduced injury in ischemia-reperfusion models, and enhanced exercise-related cardiovascular adaptation.
MOTS-c promotes osteoblast activity and may inhibit osteoclast production through RANKL suppression in preclinical research.
Human skeletal muscle cell research suggests MOTS-c may help preserve myotube area and reduce glucocorticoid-induced muscle-wasting signaling.
Animal models and CB4211 human data suggest potential liver-support effects, including reductions in ALT and AST biomarkers.
Sign in or create a free account to view this content.
Wash hands, clean the work surface, and wipe vial stoppers with alcohol. Allow them to dry.
For the 10mg vial example, add 2mL bacteriostatic saline down the inside vial wall. This gives 5mg/mL.
Gently swirl; do not shake aggressively.
Refrigerate after reconstitution and protect from light. Record the mixing date and final concentration in your research journal.
NAD+ is the fuel for the energy system that MOTS-c is optimizing. MOTS-c pushes metabolic signaling; NAD+ supports the raw material needed for energy production.
5-Amino-1MQ inhibits NNMT, helping reduce NAD+ waste. In the engine analogy, it helps fix the exhaust leak so fuel is recycled more efficiently.
Retatrutide, semaglutide, and tirzepatide handle the intake side through appetite and gastric emptying. MOTS-c supports cellular fuel utilization.
If mitochondrial dysfunction is significant, repair first with SS-31. If decline is moderate, concurrent use may be reasonable.
MOTS-c sends the signal, NAD+ supplies the fuel, and 5-Amino-1MQ helps preserve fuel availability. This makes MOTS-c central to a broader mitochondrial optimization stack.
The closest human safety data comes from CB4211, a stabilized MOTS-c analog. In Phase 1a/1b testing, it was generally well tolerated with no serious adverse events reported, although native MOTS-c itself still has limited direct human safety data.
MOTS-c is one of the highest-ROI peptides in the mito/longevity category right now. This mitochondrial-derived peptide punches way above its weight for energy, fat oxidation, and metabolic flexibility. Community feedback and preclinical research consistently point to better endurance, improved insulin sensitivity, and faster recovery from metabolic stress—exactly what serious recomp and performance stacks need.
It’s not a hype peptide; it’s a tool. The strong AMPK activation makes it ideal pre-cardio, endurance work, or high-heart-rate circuits such as HIIT or CrossFit-style training. Avoid it right before heavy, pure hypertrophy sessions if maximal mTOR drive is the goal—that AMPK/mTOR interplay is real.
The only reason it doesn’t get a better grade is that injection-site reactions are real and should be monitored closely. A cycle can be going well and then, seemingly out of nowhere, a serious reaction such as hives can occur. If hives or another serious reaction occurs, treat it as a warning shot and stop using the compound.
Peptide Protocols
Send us a message and we’ll reply to the email address you provide.